About Matthew Roden
Matthew Roden is a president and CEO, director at Aktis Oncology.
Form D filings also name Matthew Roden as a director at NextPoint Therapeutics.
Matthew Roden reports to the SEC as a director or officer of 3 public companies, including iTeos Therapeutics (ITOS) and Turmeric Acquisition (TMPM).
Matthew Roden first appears on SEC filings in 2020.
Experience
This experience comes from SEC filings. The years are when the filings name Matthew Roden in the role, so the role may have started earlier or lasted longer.
NextPoint Therapeutics, Inc.
Director
2022 – 2024 · Cambridge, MA
Develops targeted cancer treatments for patients with solid tumors.
II
iTeos Therapeutics, Inc.
Director
2020 – 2022 · Public company (ITOS)
TC
Turmeric Acquisition Corp.
Director
2020 · Public company (TMPM)
Key Colleagues at Startups
The people Matthew Roden works with at each company, as listed on that company's latest Form D.
Aktis Oncology, Inc. · Form D, Oct 2, 2024
HK
Helen Kim
Director
SB
Shulamit Ron-Bigger
Executive officer
KH
Ken Herrmann
Director
LS
Lloyd Segal
Director
ON
Oleg Nodelman
Director
AL
Andrew Levin
Director
TF
Todd Foley
Director
NextPoint Therapeutics, Inc. · Form D, Feb 14, 2024
Axel Hoos
Board Member
Paulina Hill
Board Member
Ivan Cheung
Chief Executive Officer and director
Detlev Biniszkiewicz
Chairman of the Board
Rakhshita Dhar
Board Member
PC
Paul Conrad
Secretary and Treasurer
R. Jacob Vogelstein
Board Member